本次交易有利于进一步提高上市公司资产质量，促进上市公司的长远发展。本次交易完成后，上市公司 将切入到高端半导体材料领域，打造第二增长曲线，加快向新质生产力转型步伐，增加新的利润增长 点，从而进一步提高上市公司持续盈利能力。 向日葵（300111）(300111.SZ)发布公告，公司拟通过发行股份及支付现金的方式向上海兮噗等6名交易 对方购买其合计持有的兮璞材料100%股权，向向日葵投资购买其持有的贝得药业40%股权，并募集配 套资金。公司股票将于2025年9月22日(星期一)上午开市起复牌。 兮璞材料主要从事高端半导体材料的研发、制造与销售，主要产品包括半导体级高纯度电子特气、硅基 前驱体、金属基前驱体等，广泛应用于半导体制造过程中的扩散、蚀刻、薄膜沉积等关键工艺环节。贝 得药业作为向日葵的控股子公司，主要从事抗感染类、心血管类、消化系统类等药物的研发、制造和销 售。 ...

Group 1 - Global Printing announced that shareholder Hong Kong Yuanshi International Co., Ltd. plans to reduce its stake by up to 3.2004 million shares, accounting for 1% of the total share capital, due to personal funding needs [1] - Sunflower intends to acquire 100% equity of Xi Pu Materials and 40% equity of Zhejiang Beid Pharmaceutical through a combination of share issuance and cash payment, with stock resuming trading on September 22, 2025 [1][2] - Crown Zhong Ecology is planning a change in control, leading to a temporary suspension of its stock and convertible bonds due to significant uncertainties [2] Group 2 - China Oil Engineering's wholly-owned subsidiary signed a $513 million EPC contract for an LNG pipeline project in the UAE, covering approximately 180.5 kilometers of natural gas pipeline with a 36-month construction period [3] - Shanxi Fenjiu announced that shareholder Huachuang Xinrui (Hong Kong) Co., Ltd. plans to reduce its stake by up to 16.2006 million shares, representing no more than 1.33% of the total share capital [4] - Brother Technology's subsidiary received a drug registration certificate for Iopamidol injection, which is included in the national medical insurance catalog [5] Group 3 - Lin Yang Energy is expected to win a bid for a metering equipment project from the State Grid, with an estimated total bid amount of approximately 142 million yuan [6] - Huahai Chengke received approval from the China Securities Regulatory Commission for issuing shares and convertible bonds to purchase assets and raise no more than 800 million yuan in matching funds [8] - Jindi Co. signed a framework agreement to acquire controlling interest in Unico Precision, which specializes in manufacturing gears and automotive parts [10] Group 4 - Ruifeng High Materials announced that its major shareholder plans to reduce its stake by up to 2.4 million shares, accounting for 0.9584% of the total share capital [12] - Changliang Technology's director plans to reduce his stake by 1.05 million shares, representing 0.129% of the total share capital [14] - Zhongjing Food's director plans to reduce his stake by up to 150,000 shares, accounting for 0.10% of the total share capital [16] Group 5 - Haitai Technology announced that two shareholders plan to reduce their stakes by a total of up to 2.53% of the total share capital [18] - Zhenlei Technology's chairman is under detention but the company states that control has not changed and operations remain normal [20] - Huakang Co. plans to distribute a cash dividend of 0.2 yuan per share, totaling approximately 60.61 million yuan [19]

公众号记得加星标⭐️，第一时间看推送不会错过。 来源 ： 内容来自 半导体行业观察综合 。 9月21日晚，向日葵发布预案，公司拟以发行股份及支付现金的方式购买漳州兮璞材料科技有限公司 （下称"兮璞材料"）100%股权，并募集配套资金。公司股票将于9月22日复牌。 资料显示，向日葵前身为浙江向日葵光能科技有限公司，主营太阳能电池组件业务，并于2010年8月 上市。 资料显示，兮璞材料成立于2020年11月，公司多款关键产品已通过国内外多家知名晶圆厂认证，并 成为其核心供应商，整体技术达到国际先进水平。商业模式方面，公司采用"定制化代工+自主生 产"相结合的模式，通过整合国内精细化学品供应链资源，并依托漳州工厂和兰州工厂，成为国内外 多家晶圆厂的核心供应商。同时，兮璞材料深度参与客户工艺研发，以定制化方式提供一站式半导体 材料解决方案。 *免责声明：本文由作者原创。文章内容系作者个人观点，半导体行业观察转载仅为了传达一种不同的观点，不代表半导体行业观察对该 观点赞同或支持，如果有任何异议，欢迎联系半导体行业观察。 END 今天是《半导体行业观察》为您分享的第 41 6 4 期内容，欢迎关注。 推荐阅读 ★ 一颗改 ...

本次交易有利于进一步提高上市公司资产质量，促进上市公司的长远发展。本次交易完成后，上市公司 将切入到高端半导体材料领域，打造第二增长曲线，加快向新质生产力转型步伐，增加新的利润增长 点，从而进一步提高上市公司持续盈利能力。 智通财经APP讯，向日葵(300111.SZ)发布公告，公司拟通过发行股份及支付现金的方式向上海兮噗等6 名交易对方购买其合计持有的兮璞材料100%股权，向向日葵投资购买其持有的贝得药业40%股权，并 募集配套资金。公司股票将于2025年9月22日(星期一)上午开市起复牌。 兮璞材料主要从事高端半导体材料的研发、制造与销售，主要产品包括半导体级高纯度电子特气、硅基 前驱体、金属基前驱体等，广泛应用于半导体制造过程中的扩散、蚀刻、薄膜沉积等关键工艺环节。贝 得药业作为向日葵的控股子公司，主要从事抗感染类、心血管类、消化系统类等药物的研发、制造和销 售。 ...

转自：证券时报 人民财讯9月21日电，向日葵(300111)9月21日公告，公司拟以发行股份及支付现金的方式购买漳州兮璞 材料科技有限公司（简称"兮璞材料"）100%股权、浙江贝得药业有限公司40%股权并募集配套资金。 公司股票将于2025年9月22日复牌。兮璞材料主要从事高端半导体材料的研发、制造与销售，主要产品 包括半导体级高纯度电子特气、硅基前驱体、金属基前驱体等，广泛应用于半导体制造过程中的扩散、 蚀刻、薄膜沉积等关键工艺环节。贝得药业作为向日葵的控股子公司，主要从事抗感染类、心血管类、 消化系统类等药物的研发、制造和销售。 ...

Core Viewpoint - Sunflower is planning a significant asset restructuring by acquiring controlling stakes in two companies, aiming to expand its business into the semiconductor materials sector while consolidating its pharmaceutical operations [1][9]. Group 1: Acquisition Details - The company announced plans to acquire the controlling stake in Zhangzhou Xipu Materials Technology Co., Ltd. and 40% of Zhejiang Beid Pharmaceutical Co., Ltd. through share issuance and/or cash payment [1]. - The transaction is expected to constitute a major asset restructuring and will not lead to a change in the actual controller of the company [1]. - The stock will be suspended from trading starting September 8, 2025, with the transaction plan to be disclosed within 10 trading days [1]. Group 2: Company Background and Business Transition - Sunflower, established in 2005, initially focused on solar energy products and has undergone several transitions, including a name change to Zhejiang Sunflower Health Technology Co., Ltd. in 2020, focusing on pharmaceutical products [7][8]. - The company has previously attempted to diversify into various sectors, including pharmaceuticals and high-tech materials, but faced challenges due to market fluctuations and technical issues [8]. - The current acquisition is seen as another attempt to pivot towards high-growth sectors, particularly in semiconductor materials, which may help reverse the declining performance in its existing business segments [15]. Group 3: Financial Performance - In the first half of 2025, the company reported revenue of approximately 144 million yuan, a year-on-year decrease of 8.33%, and a net profit of only 1.16 million yuan, down 35.68% [12]. - The financial struggles have prompted the company to explore frequent cross-industry transformations, reflecting challenges in its current business operations, especially in the pharmaceutical sector [12][14]. - The company aims to leverage the high growth potential of the semiconductor materials industry to improve its financial performance [15].

Group 1: Mergers and Acquisitions Overview - During the period from August 22 to August 28, 2025, three listed companies announced new mergers and acquisitions, namely Debang Lighting, Dongzhu Ecology, and Nanxin Pharmaceutical, involving three M&A events across the home appliances, construction decoration, and pharmaceutical industries [1][9]. Group 2: Debang Lighting - Debang Lighting focuses on the research, production, and sales of lighting application products, covering general lighting and automotive lighting. In 2024, the company achieved a revenue of 4.431 billion yuan, with general lighting contributing the most at 3.785 billion yuan, although it saw a year-on-year decline of 6.35%. The automotive lighting segment generated 596 million yuan, down 4.43% year-on-year, while the lighting engineering construction business earned 114 million yuan, down 36.48% [2][9]. - The cost structure shows that material costs are significant, accounting for 86.64% and 79.48% in general and automotive lighting, respectively. The company enhances manufacturing levels through "efficiency + flexibility" production methods and employs information management systems like MES, SCM, and ERP to optimize supply chains and production processes [2][9]. - Debang Lighting plans to acquire at least 51% of Jiali Co., a well-known domestic automotive lighting manufacturer, through cash and capital increase [2][9]. Group 3: Dongzhu Ecology - Dongzhu Ecology is a comprehensive enterprise focused on ecological protection and environmental governance, with business areas including wetland protection, water environment governance, municipal landscape, and forest park management. In 2024, the company undertook several key projects, including ecological restoration and municipal infrastructure projects [3][10]. - The company plans to acquire a controlling stake in Kairuixing Technology (Nanjing) Co., Ltd. through a combination of issuing shares and cash payments, aiming to raise supporting funds. Kairuixing operates in satellite communication services and intelligent UAV manufacturing [3][10]. Group 4: Nanxin Pharmaceutical - Nanxin Pharmaceutical specializes in the research, production, and sales of antiviral and infectious disease prevention drugs, as well as treatments for major diseases like cardiovascular diseases and diabetes. The company has established a research and development system combining innovative and generic drugs [4][11]. - The company has launched the first domestic 1.1 class innovative drug for influenza, along with various oral medications, creating a product line that includes injection and oral administration routes. Nanxin Pharmaceutical signed an acquisition agreement to purchase a group of assets related to multiple trace element injection solutions for up to 480 million yuan [5][12]. - The assets include already marketed products and ongoing research projects, targeting the nutritional needs of children and adults [5][12].

深交所决定终止ST普利股票及可转债上市，这一决策意味着ST普利将彻底告别证券交易所的交易舞台。公司股票及可转债进入退市整理期，起始日为 2025年4月28日，时长十五个交易日，预计最后交易日期为2025年5月21日。 2025年4月18日晚间，*ST普利发布公告，称公司于当日收到深交所《关于海南普利制药股份有限公司股票及可转换公司债券终止上市的决定》。 | 证券代码:300630 | 证券简称:*ST 普利 | 公告编号:2025-044 | | --- | --- | --- | | 债券代码:123099 | 债券简称:普利转债 | | 值得关注的是，目前普利制药显示长期停牌，这源于其严重的财务造假问题。2025年1月4日，公司收到中国证监会《行政处罚事先告知书》，被指在 2021-2022年间，通过虚构成品药、原料药销售业务及不合理贸易业务核算方式，虚增收入与利润，致使这两年年度报告严重虚假。 随后（1月6日），普利制药股票停牌一天；1月7日起，公司被实施重大违法强制退市风险警示，股票简称变更为"*ST普利"。3月21日，证监会表明对严 重财务造假主体将全方位追责，同日深交所依规启动其股票终止上市程序。 ...